Participated · Seed · Mar 2026

Excalipoint Therapeutics is a clinical-stage biotechnology company focused on discovering and developing T-cell engager (TCE) therapies for oncology and immunology indications. Its pipeline includes tri- and multi-specific antibody programs such as EXP011 (CTM012) targeting DLL3/CD3/4-1BB—entered Phase I/II with first patient dosed in October 2025—EXP012 (CTM013) targeting CDH17/CD3/4-1BB, and additional programs (EXP016, EXP017, EP101, EXP015) built on its TOPAbody, Immune Shield, and Pro-TCE platform technologies. The company is led by CEO Lei Fang and CFO Jielun Zhu. Following the $68.7M Seed raise, Excalipoint intends to use the funds to advance its proprietary platforms and progress its pipeline programs through clinical development.

Participated · Series A · Nov 2025

Founded in 2022, Phrontline Biopharma focuses on creating bispecific antibody ADCs (BsAb-ADCs) and dual-payload ADCs that combine two tumor targets and complementary cytotoxic payloads. The company has built an end-to-end platform covering antibody discovery, linker-payload engineering, site-specific conjugation, and functional characterization, giving it a proprietary technology engine for differentiated ADCs. Leveraging this platform, Phrontline has advanced nearly ten ADC programs, including its lead candidate TJ101, an EGFR/B7-H3 bispecific ADC now in first-in-human trials in China and the United States. Early preclinical data show TJ101 delivers superior efficacy and safety relative to peer programs. To accelerate development, Phrontline signed a global co-development pact with Samsung Bioepis for two bispecific, dual-payload ADCs and licensed China rights to TJ101 to Sino Biopharmaceutical in exchange for upfront, milestone, and royalty payments. The firm intends to use new capital to expand global clinical operations, strengthen strategic partnerships, and progress both clinical-stage and preclinical assets. No revenue or patient outcome metrics have been disclosed to date.

Participated · Series A · Nov 2024

Founded in 2023, Shanghai-based Allink Biotherapeutics is a clinical-stage biotechnology company focused on creating advanced ADCs and multi-specific antibody therapies. Its two lead candidates, ALK201 (an FGFR2b-targeted ADC) and ALK202 (an EGFR/cMET bispecific ADC), are already in global Phase I trials and have shown encouraging early efficacy and safety signals across multiple tumor types. The firm is pursuing a biomarker-guided strategy and plans to initiate combination studies to broaden the clinical reach of these assets and prepare them for pivotal trials. Beyond its ADC programs, AllinkBio is building a proprietary masked T-cell engager platform and a pipeline of first-in-class bi- and multi-specific antibodies aimed at underserved patient populations. The company emphasizes rapid R&D execution and platform innovation to maintain competitive differentiation. The recent $47 million Series A extension financing underscores strong investor confidence and provides the capital required to advance lead programs and expand discovery efforts.

Led · Series A · Feb 2024

Ruibijia (杭州瑞彼加医疗科技有限公司) develops precision‑controlled MEMS radiofrequency (micro‑RF) technology for control and rehabilitation of neuron‑related diseases and aesthetic applications. The core technology was developed by a team with years of R&D and productization experience in top universities and Fortune 500 companies, and the company says its micro‑RF surpasses comparable Western products. Ruibijia has obtained patent certifications in China and the U.S. and has been identified as the first domestic provider for parts of its technology. Its first commercial product was the Precision OAB Treatment Device (for urinary frequency), classified as a Class II medical device by Zhejiang regulators in November 2016 and admitted to a Zhejiang special approval channel in September 2017; related catheter and host registrations completed in 2018. The company also markets the nebulyft® RF beauty device built on an RFMEMS patent (development originating in Irvine, California). Ruibijia has received multiple local talent and innovation recognitions since 2015 and is actively recruiting in Hangzhou, Beijing, and Shanghai. Rebeccatech develops biocompatible microelectromechanical RF technology and has built devices targeting multiple specialty applications, including urology, hepatology, and dermatology. The company markets a skincare line under the sub-brand NEBULYFT, a micro‑RF beauty device. It has published research on its micro‑RF therapies and secured support from domestic and international urology experts. Rebeccatech is working with internet healthcare platforms such as JD Health to promote its new therapies to patient and physician communities and to develop additional indications. Financially, the company completed an A round this year for several tens of millions of RMB and previously raised a Pre‑A and an angel round. The founder, Dr. Zhang Yang, holds degrees and postdoctoral experience from University of Science and Technology of China, UC Irvine, and UCLA and has industry and accelerator leadership experience.

Participated · Equity · May 2023

Larkspur Biosciences develops precision cancer immunotherapies using its proprietary LarkX platform, which leverages patient genetics, immune phenotypes, bioinformatics, and complex in vitro models to discover immune-evasion signatures. Its lead programs include an approach to lipid remodeling intended to uncloak tumors and a program targeting Pin1, a mechanism of fibroblast differentiation to activate immune cells. The company’s initial clinical strategy targets a genetically- and immunologically-characterized subtype of colorectal cancer whose patients have T cells at the tumor and can be identified via biopsy. Larkspur positions these insights as applicable across multiple cancer indications that share evasion signatures. The company is led by CEO Catherine Sabatos-Peyton and was founded by Drs. Lewis Cantley, Nathanael Gray, and Vijay K. Kuchroo. It raised financing to advance IND-enabling studies and further ongoing preclinical work.